ReviewTherapeutic advances in musculoskeletal disease2020
Setting up distinctive outcome measures for each osteoarthritis phenotype.
Review in Therapeutic advances in musculoskeletal disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Advances in heterogeneity and classification of osteoarthritis.Bone research · 2026Review
- Metabolic liver burden and osteoarthritis prevalence: A comparative analysis of noninvasive hepatic indices.Medicine · 2026Article
- Natural products and immune-cell responses in osteoarthritis: mechanisms, evidence maturity, and translational gaps.Frontiers in immunology · 2026Review
- Gender-differences in imaging phenotypes of osteoarthritis in the osteoarthritis initiative.Scientific reports · 2025Article
- MicroRNA Signatures in Cartilage Ageing and Osteoarthritis.Biomedicines · 2023Article
- Identification of S100A8 as a common diagnostic biomarkers and exploring potential pathogenesis for osteoarthritis and metabolic syndrome.Frontiers in immunology · 2023Article
- Screening Clinical Changes for the Diagnosis of Early Knee Osteoarthritis: A Cross-Sectional Observational Study.Diagnostics (Basel, Switzerland) · 2022Article
- Osteoarthritis: Mechanistic Insights, Senescence, and Novel Therapeutic Opportunities.Bioelectricity · 2022Article
- Moving toward targeting the right phenotype with the right platelet-rich plasma (PRP) formulation for knee osteoarthritis.Therapeutic advances in musculoskeletal disease · 2021Review
- New Trends in Pharmacological Treatments for Osteoarthritis.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is an evolving chronic joint disease with a huge global impact. Given the intricate nature of the etiopathogenesis and subsequent high heterogeneity in the clinical course of OA, it is crucial to discriminate between etiopathogenic endotypes and clinical phenotypes, especially in the early stages of the disease. In this sense, we propose that an OA phenotype should be properly assessed with a set of outcome measures including those specifically related to the main underlying pathophysiological mechanisms. Thus, each OA phenotype can be related to different and clinically meaningful outcomes. OA phenotyping would lead to an adequate patient stratification in well-designed clinical trials and the discovery of precise therapeutic approaches. A significant effort will be required in this field in light of inconclusive results of clinical trials of tissue-targeting agents for the treatment of OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.